Latest Angiolutions News
Feb 17, 2021
Angiolutions’ novel vascular implant defuses the abdominal ticking time bomb The award-winning medtech startup Angiolutions successfully secured its seed financing round with High-Tech Gründerfonds, FRIBA Investment and NBank Capital. Using its latest innovative technology based on the founders’ academic research, the company aims to prevent the deadly progression of small abdominal aortic aneurysms. The investment will enable the next critical steps regarding device development. We are thrilled to have a strong investor syndicate enabling the successful completion of our next critical R&D steps. Dr. Uwe Raaz and Dr. Isabel N. Schellinger, founders of Angiolutions Angiolutions aims to stop aneurysm progression at an early stage through its novel, minimally invasive device-based therapy. An abdominal aortic aneurysm is a bulging of the abdominal aorta. With increasing aortic diameter, the risk of fatal rupture rises. In case of rupture mortality rates are concerningly high (approximately 80% of the cases). While globally about 4,8% of the male population are affected there currently is no therapy available to stop aneurysm growth. Originating from a strong academic background, the founding team of Angiolutions utilizes its latest research findings to develop a disruptive new method to treat small aneurysm disease. The founders, Dr. Uwe Raaz and Dr. Isabel N. Schellinger, with their longstanding clinical and scientific experience in the cardiovascular field, convinced us right from the start. Dr. Anke Caßing, Senior Investment Manager at High-Tech Gründerfonds Their work has let them to prestigious intuitions around the world and earned them respected merits from the medical (e.g. German society of vascular medicine) and entrepreneurial (e.g. FORBES) community alike. About Angiolutions Angiolutions specializes in device-based innovation in vascular medicine. Angiolutions is a Germany based company that develops therapeutic devices for vascular diseases. We combine latest biomechanical, biological and molecular research with traditional engineering excellence to create novel ingenious tools to tackle the challenging unmet needs in vascular medicine. Contact us via firstname.lastname@example.org About FRIBA Investment About FRIBA Investment: FRIBA Investment is a German Single Family Office. Our industrial heritage dates back more than 140 years and stems from an entrepreneurially driven, operating business. Today, we continue to enjoy working with inspirational founders, entrepreneurs and like-minded families around the globe. FRIBA focuses on direct investments in private equity, real estate and venture capital backed companies and projects. About NBANK The NBank is the key contact for all relevant development funding programmes of the European Union, Germany, Lower Saxony and the municipalities. We lend our support to people, companies, municipalities, institutions and ideas. As development bank of the German federal state of Lower Saxony we work to develop solutions for fostering growth and enhancing the quality of life in Lower Saxony. About NBank Capital The NBank Capital Beteiligungsgesellschaft mbH, as subsidiary of the NBank, supports start-ups and established enterprises based in Lower Saxony with investment capital to strengthen their capital base and thereby finance growth and innovation. About High-Tech Gründerfonds High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected almost EUR 3 billion into the HTGF portfolio via more than 1,700 follow-on financing rounds. HTGF has also successfully sold interests in more than 120 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Bank, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.